KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Amgen (AMGN) over the last 17 years, with Q3 2025 value amounting to $52.4 billion.

  • Amgen's Non-Current Debt fell 777.43% to $52.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 billion, marking a year-over-year decrease of 777.43%. This contributed to the annual value of $56.5 billion for FY2024, which is 1048.12% down from last year.
  • Amgen's Non-Current Debt amounted to $52.4 billion in Q3 2025, which was down 777.43% from $53.8 billion recorded in Q2 2025.
  • In the past 5 years, Amgen's Non-Current Debt ranged from a high of $63.2 billion in Q4 2023 and a low of $28.5 billion during Q2 2021
  • For the 5-year period, Amgen's Non-Current Debt averaged around $47.7 billion, with its median value being $53.8 billion (2025).
  • Per our database at Business Quant, Amgen's Non-Current Debt crashed by 1662.61% in 2021 and then surged by 6911.17% in 2023.
  • Over the past 5 years, Amgen's Non-Current Debt (Quarter) stood at $33.2 billion in 2021, then grew by 12.44% to $37.4 billion in 2022, then skyrocketed by 69.11% to $63.2 billion in 2023, then dropped by 10.48% to $56.5 billion in 2024, then dropped by 7.28% to $52.4 billion in 2025.
  • Its last three reported values are $52.4 billion in Q3 2025, $53.8 billion for Q2 2025, and $54.0 billion during Q1 2025.